Bioline Rx (BLRX) AI Stock Analysis

• Market Cap: 52.22M
• Dividend Yield: N/A
• Average Volume (3M): 4.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.93
• Revenue Growth: -42.69%
• EPS Growth: 88.04%
• Country: IL
• Employees: 28
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 2,610,814,500
• 10 Day Avg. Volume: 5,813,402
• 30 Day Avg. Volume: 4,637,561
• PEG Ratio: 0.03
• Price to Book (P/B): 1.59
• Price to Sales (P/S): 0.74
• P/FCF Ratio: -0.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: 2.00 ▲(11.11% Upside)

The overall stock score is primarily influenced by financial performance challenges, including profitability and cash flow issues. Technical indicators suggest bearish momentum, while valuation metrics are weak due to negative earnings. The earnings call provided some positive strategic insights, but operational reductions offset these gains.

Positive Factors

Strategic Joint Venture

The joint venture with Hemispherian to develop GLIX1 for glioblastoma expands BioLineRx's pipeline and leverages expertise in DNA damage response, potentially enhancing long-term growth prospects in the oncology market.

Patent Protection

The patent protection for GLIX1 until 2040 ensures a competitive advantage and secures long-term revenue potential from this innovative cancer treatment.

Cash Position and Financial Health

A strong cash position provides financial stability and supports ongoing R&D and operational activities, crucial for sustaining long-term growth and development efforts.

Negative Factors

Decreased R&D Expenses

Reduced R&D spending may limit future innovation and development capabilities, potentially impacting the company's ability to sustain its competitive edge in the long term.

No Sales and Marketing Expenses

The elimination of sales and marketing expenses may hinder the company's ability to effectively commercialize its products, impacting long-term revenue growth and market presence.

High Leverage and Financial Instability

Increased leverage and negative equity returns highlight financial instability, posing long-term risks to cash flow and operational flexibility if not addressed.

Bioline Rx Business Overview & Revenue Model

Company Description

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

How the Company Makes Money

Bioline Rx generates revenue through several key streams, primarily from the development and commercialization of its therapeutic candidates. The company engages in strategic partnerships and collaborations with larger pharmaceutical firms, which often involve upfront payments, milestone payments based on development progress, and royalties on future sales of products. Additionally, Bioline Rx may receive funding through government grants or research contracts aimed at advancing its clinical programs. The successful development and eventual market approval of its drug candidates are critical for the company’s revenue growth, as they position the firm to benefit from product sales and licensing agreements.

Bioline Rx Financial Statement Overview

Summary

Bioline Rx is experiencing revenue growth, indicating potential market demand. However, significant challenges in profitability and cash flow management persist. High leverage and negative equity returns highlight financial instability, posing risks if not addressed.

Income Statement

The company showed a significant increase in total revenue from 2023 to 2024, which is a positive sign of growth. However, the net profit margin remains negative due to substantial net losses, indicating ongoing financial challenges. The EBIT and EBITDA margins are also negative, reflecting inefficiencies in operations. Overall, while revenue growth is promising, profitability remains a concern.

Balance Sheet

The debt-to-equity ratio increased, indicating higher leverage, which could be risky. The return on equity remains negative due to net losses, pointing to poor returns for shareholders. The equity ratio has decreased, suggesting reduced financial stability. Although the company has a strong asset base, the increased liabilities and negative equity returns are significant weaknesses.

Cash Flow

The operating cash flow is negative, underscoring cash flow challenges. Free cash flow has also significantly declined, reflecting poor cash management. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. Despite some cash inflows from financing activities, the company struggles to generate positive cash flow, which could hinder its ability to fund operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	17.25M	28.94M	4.80M	0.00	0.00	0.00
Gross Profit	10.23M	19.68M	1.11M	0.00	0.00	0.00
EBITDA	1.97M	3.92M	-57.09M	-28.50M	-24.07M	-21.99M
Net Income	-7.82M	-9.22M	-60.61M	-20.75M	-28.14M	-30.93M
Balance Sheet
Total Assets	43.27M	38.91M	63.92M	76.38M	81.39M	47.29M
Cash, Cash Equivalents and Short-Term Investments	28.16M	19.56M	42.99M	51.08M	57.13M	22.59M
Total Debt	12.60M	15.04M	11.59M	12.32M	4.65M	7.68M
Total Liabilities	23.20M	25.45M	50.70M	25.54M	13.30M	25.26M
Stockholders Equity	20.07M	13.46M	13.22M	50.84M	68.09M	22.03M
Cash Flow
Free Cash Flow	-21.20M	-43.93M	-22.91M	-26.56M	-23.67M	-23.21M
Operating Cash Flow	-21.20M	-43.87M	-22.61M	-26.24M	-23.57M	-23.21M
Investing Cash Flow	9.45M	29.37M	1.44M	4.01M	-38.22M	16.67M
Financing Cash Flow	8.72M	20.66M	15.06M	20.44M	57.75M	17.87M

Bioline Rx Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Negative. The current price of 1.8 is below the 20-day moving average (MA) of 1.86, below the 50-day MA of 2.03, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 42.03 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BLRX.

Bioline Rx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BLRX	46 Neutral	52.22M	-0.77	―	―	-42.69%	88.04%
CANF	43 Neutral	51.22M	―	―	―	―	―